Invalidity dossier
US 3674840
1-(para-alkoxyalkoxy-phenyl)-2-hydroxy-3-alkylaminopropanes and the salts thereof
Current assignee: Individual
Added 9/21/2026, 3:58:32 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 3,674,840 A
Title: "1-(para-alkoxyalkoxy-phenyl)-2-hydroxy-3-alkylaminopropanes and the salts thereof"
Source: https://patents.google.com/patent/US3674840/en
Key formal details (from the supplied text):
- Publication number: US3674840A
- Application number: US38884A
- Prior art date / priority date (as listed, noted as an assumption): 1969-05-21
- Filing date: 1970-05-19
- Publication/grant date: 1972-07-04
- Inventors: Arne Elof Grandstrom; Per Arvid Emil Carlsson; Stig Ake Ingemar Carlsson; Hans Rudolf Corrodi; Lars Ek; Bo Robert Lamm; Bengt Arne Hjalmar Ablad
- Original assignee / current assignee (as listed): Individual
- Status: Expired – Lifetime; anticipated expiration 1989-07-04
- Cited related compounds in the text include isoprenaline, adrenaline, alprenolol, and oxprenolol.
Purpose and plain-language scope (based only on the supplied text):
The patent concerns a class of chemical compounds — 1-(para-alkoxyalkoxy-phenyl)-2-hydroxy-3-alkylaminopropanes — together with their salts, including non-toxic acid addition salts. The document associates these compounds with pharmaceutical compositions and with cardiovascular disease, beta-adrenergic receptors, cardiac effects, and bronchi/trachea (suggesting beta-blocking or related pharmacological activity). Named substituent groups appearing in the text include isopropyl, tert-butyl, and 2-methoxyethyl. Example compounds and intermediates listed include 4-(2-methoxyethoxy)phenol, 2-[[4-(2-methoxyethoxy)phenoxy]methyl]oxirane, and 3-(phenoxyamino)propan-1-ol. Reaction and purification reagents mentioned include hydrochloric acid, epichlorohydrin, isopropylamine, ammonia, potassium carbonate, and palladium.
What the supplied excerpt does not establish:
- The full text of the claims, including the exact claimed substituent ranges and markush definitions.
- Whether any specific compound is expressly claimed or only exemplified.
- Detailed synthesis procedures, dosages, or clinical data (only fragmentary reagents, solvents, and test references appear).
- The identity of the true owner or any assignments (the listed "Individual" assignee is expressly described as possibly inaccurate).
- Any legal conclusion on validity, enforceability, or infringement; the legal status shown is expressly an assumption and not a legal conclusion.
All statements above are limited to the supplied source text.
Generated 10/1/2026, 10:00:49 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 3674840. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.